Tutorials: Feb 1, 2012 (Vol. 32, No. 3)

Disulfide-Bonded Protein Production in E. coli

Involvement of Disulfide Bond Isomerase Improves Protein Folding

(Page 1 of 2)

    Disulfide bonds are an essential stabilizing feature of many proteins. More than 50% of human ER proteins are estimated to contain disulfide bonds (dsb) and the majority of secreted proteins also contain dsbs.

    Using bacteria to produce these proteins efficiently presents a significant challenge because the correct pairing of cysteines in a protein with multiple disulfide bonds is inherently fraught with error. Misoxidation of the incorrect pairs of cysteines results in misfolding and low yields.

    Nature has resolved this issue by shuffling the incorrect disulfide bonds in misfolded protein into their native correct pairing by the activity of disulfide bond isomerases. Protein disulfide isomerase (PDI) carries out dsb oxidation and isomerization in the ER of all eukaryotes.

    In many Gram-negative bacteria (including E. coli) the cooperative action of DsbA and DsbC oxidizes proteins within the periplasmic space. This is also true within commonly used E. coli protein-expression strains, with the exception of engineered strains such as the Origami™ strains from EMD Biosciences and the SHuffle® strains from New England Biolabs. These commercial strains have been similarly engineered to possess an oxidative cytoplasmic environment that favors disulfide bond formation. The SHuffle strains have been further modified to support robust production of dsb-containing proteins.

    Dsb Formation in the SHuffle Strains

    SHuffle strains contain a unique trio of modifications that produce robust disulfide bond formation in the cytoplasm.

    First, the cytoplasmic environment is altered by elimination of glutathione reductase (gor gene product) and thioredoxin reductase (trxB gene product). Since the combination of gor and trxB deletions are lethal, a suppressor mutation in the ahpC gene is necessary for the SHuffle (and Origami) strains to maintain viability.

    Second, SHuffle strains are uniquely engineered to overexpress DsbC within the cytoplasm. The DsbC enzyme acts as a disulfide bond isomerase and “shuffles” mis-oxidized cysteine pairs allowing the recombinant target protein to achieve its properly folded confirmation. Due to the action of DsbC in the SHuffle cell, less target protein proceeds down the paths of protease degradation or inclusion body formation.

    Finally, the SHuffle strains were engineered from robust parent strains capable of tightly controlled protein expression. For example, SHuffle T7 Express (B strain) and SHuffle T7 (K-12 strain) both express the T7 RNA polymerase from the lac operon, whereas most other T7 expression strains utilize the DE3 prophage.

    T7 expression in DE3 strains is known to be somewhat uncontrolled and this can have very detrimental effects on cell growth and protein yield when the target protein is even mildly toxic, which is a common occurrence with heterologous dsb-containing proteins. If strictly controlled T7 expression is required, then lysY strains are also available.

    The lysY gene product is a variant of T7 lysozyme containing a mutation that eliminates “lysozyme” function on the E. coli cell wall, but the ability of LysY to inhibit T7 RNA polymerase function is unaffected. During the pre-induction phase, a constant low level of LysY inhibitor protein is produced to inactivate any basal expression of T7 RNA polymerase.


Related content

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe

e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
  Confirm Email
  First Name
  Last Name
  Organization
  E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

FDA Performance

How much progress do you think FDA has made in reviewing drugs and bringing them to market faster?

Suggest a Poll